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Abstract
Phospholipid transfer protein (PLTP) is an important modulator of lipoprotein metabolism,
including interparticle phospholipid transfer, remodeling of HDL, cholesterol and phospholipid
efflux from peripheral tissues, and the production of hepatic VLDL. PLTP also plays an important
role in inflammation and oxidative stress. Accordingly, PLTP has been implicated in the
development of atherosclerosis. In this study, we evaluated the association between PLTP activity
and lipoprotein metabolism in a Chinese patients cohort with or without coronary heart disease
(CHD group n = 407, control group n = 215), the PLTP activity was measured and PLTP genotyping
was screened for sequence anomalies by PCR. We found that human plasma PLTP activity was
negatively associated with plasma HDL and apoA-I levels, and positively associated with plasma TG,
apoB and apoE levels. We also found that PLTP rs2294213 polymorphism was tended to be
associated with increased plasma PLTP activity.
Plasma phospholipid transfer protein (PLTP) is a lipid
transfer glycoprotein that binds to and transfers a number
of compounds including phospholipids, diacylglycerides,
unesterified cholesterol, and lipopolysaccharidesl. In
humans, PLTP activity has been shown to be positively
and independently related to coronary heart disease
(CHD) [1] In addition, previous studies showed that PLTP
activity was increased with aging [2], obesity [3,4], type 1
and type 2 diabetes [4-6]. It is known that PLTP is
involved in high-density-lipoprotein (HDL) metabolism
in that human plasma PLTP activity was either positively
[7,8] or negatively[2,9] correlated with HDL levels in var-
ious patient populations.
PLTP deficiency has not been found in humans while
numerous PLTP polymorphisms were identified. Tahva-
nainen et al. reported 6 PLTP intragenic polymorphisms:
c.-79G>T, c. -56G>A, c.-37T>C, c.-31A>G, p.Phe2Leu,
Arg121Trp, and 2 neutral polymorphisms, however, there
were no significant associations between these polymor-
phisms and plasma PLTP activity[2]. Similarly, Bossé and
coworkers identified 2 intronic variants of the PLTP gene,
1 in intron 1 (c.-87G>A) and the other in intron 12
(c.1175+68T>G)[10]. Although both of these polymor-
phisms were associated with obesity-related phenotypes
but there was still no significant associations between
these polymorphisms and plasma PLTP activity [10].
Aouizerat and colleagues observed p.R235W mutation
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but not p.E72G, p.S119A, and p.S124Y in the PLTP codon
region was related to decreased plasma PLTP activity and
c.-34G>C allele was associated with higher HDL-C [11]. It
was also reported that possession of the rs2294213 minor
allele could increase HDL-C independent of triglycer-
ides[12], but it remains unknown whether this polymor-
phism could influence PLTP activity and is linked with
coronary heart disease(CHD) or not. In the present study,
we confirmed the PLTP polymorphism (rs2294213) in a
Chinese population and evaluate its relationship with
plasma PLTP activity, lipid profiles and CHD.
Methods
Study Population
A total of 622 subjects underwent diagnostic coronary
angiography for chest pain in Zhongshan Hospital
between 2004 and 2005 were included in this study. Car-
diovascular risk factors/diseases were obtained by clinical
history. Coronary artery disease (CHD) (n = 407) was
diagnosed with the presence of a stenosis ≥50% in at least
1 major coronary artery territory (left anterior descending,
left circumflex or right coronary artery). Subjects who had
<50% stenosis in any coronary artery served as the con-
trols (n = 215). Exclusion criteria were evidence of signif-
icant concomitant cardiac and non-cardiac disease
including severe valvular heart disease, known cardiomy-
opathy, malignancy, or febrile condition. Diabetes melli-
tus was diagnosed by clinical history, use of hypoglycemic
medications or a fasting blood sugar level >7.0 mmol/L
(125 mg/dL); hypertension was defined in patients receiv-
ing antihypertensive treatment or with known diagnosis
of hypertension (blood pressure ≥140/90 mmHg). The
study was approved by the Institutional Review Boards of
Fudan University.
Laboratory Evaluation
Subjects were advised to fast for at least 8 hours prior to
blood sampling. Lipid profile was determined with
Hitachi 7600 biochemistry autoanalyzer. Triglyceride
(TG), total cholesterol (TC) and high-density lipoprotein-
cholesterol (HDL-C) were measured with enzymatic
methods (TG, Shanghai Kehuadongling Diagnostics Co.,
Ltd.; TC, Shanghai Kehuadongling Diagnostics Co., Ltd.;
HDL-C, PEG-modified enzyme HDL-C assay, Kyowa
Medex Co.). Low-density lipoprotein-cholesterol (LDL-C)
was calculated according to the Friedewald formula.
ApoA-I, apoE, apoB, and Lipoprotein(a) [Lp(a)] were
determined by immunoturbidimetric assays (apoA-I, apo
E, and apo B, DiaSyA Diagnostics; Lp(a), Nittobo Boseki
Co. Ltd).
PLTP Genotyping
PLTP genotype was identified for each subject by genomic
DNA PCR using sense primer TAAAGGCGGCT-
GGAACAACCCTG-3' and anti-sense primer GCGTTCTC-
CTTCATCGGCTCT-3'. The SNP reference number was
identified by placing the flanking sequences with 30 base
paires from each side of the SNP into the NCBI SNP data-
base to do BLAST analysis. The polymorphism
(rs2294213) is located on PLTP gene Intron 1.
PLTP Activity Assay
PLTP activity was measured with an assay kit (Cardiovas-
cular Targets Inc., New York, NY, USA). The kit includes
both donor and acceptor particles. Incubation of donor
and acceptor particles with 3 μl of human plasma results
in PLTP-mediated transfer of fluorescent phospholipid,
which is present in a self-quenched state when associated
with the donor. The transfer is determined by the increase
in fluorescence intensity as the fluorescent lipid is
removed from the donor and transferred to the acceptor.
The interassay coefficient of variation of the PLTP activity
was 3.3 ± 0.5%. The linear range of PLTP activity in this
assay was between 1 and 7 μl of plasma. Three freeze-thaw
cycles of plasma did not influence the assay. To validate
the novel PLTP activity assay, we compared the results
with those obtained by the classic radiolabeled method
[13,14] There was a high degree of correlation between
the 2 methods (r = 0.90, p < 0.01; n = 30). Laboratory per-
sonnel were unaware of the study individual assignation.
Statistical Methods
The study subjects were grouped according to their PLTP
genotype. Continuous variables were reported as means ±
standard deviation (SD) and univariate analysis of vari-
ance tests were used to test statistical significance. The
Pearson's X2 test statistic was used to assess statistically sig-
nificant differences in proportions for dichotomous and
categorical variables. The distribution of PLTP activity and
Lp(a) levels was positively skewed and so were naturally
log transformed prior to analyses. Multivariate analysis of
variance was performed to evaluate the relationship
between PLTP genotype and PLTP activity level. The
dependent variable was log transformed PLTP activity
level. The independent variables included PLTP genotype,
gender, and presence/absence of diabetes, hypertension,
smoking, low HDL and CHD. Age and BMI were entered
into the model as covariates. Selected interaction effects
were tested between the independent variables in the
model. Estimated geometric means of PLTP activity level
were generated for each independent variable using
reverse-log transformation of the ANOVA generated mar-
ginal means. LSD test was performed for multiple com-
parisons. To further investigate the relationship between
PLTP activity and plasma lipid parameters, univariate and
multivariate linear regression analyses were performed
and estimated expected change in PLTP activity was deter-
mined for a unit change in each lipid parameter. All anal-
yses were done using SPSS version 17 analytical software
(SPSS Inc., Chicago, IL).Nutrition & Metabolism 2009, 6:49 http://www.nutritionandmetabolism.com/content/6/1/49
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Results
Based on genomic DNA PCR and sequence, we detected
the rs2294213 PLTP polymorphism which is located on
PLTP gene Intron 1. Of the 622 subjects, 277 (44.5%) had
'GG' polymorphism PLTP genotype, 276 (44.4%) had
'CG' PLTP genotype and 69 (11.1%) had 'CC' polymor-
phism. Obtained genotype frequencies were compared to
the calculated frequencies based on the Hardy-Weinberg
equilibrium and no significant differences were observed
(χ2 = 0.000631, P = 0.980 for all participants; χ2 = 1.443,
P = 0.230 for the control group; χ2 = 0.708, P = 0.400 for
the CHD patient group). The clinical characteristics of
studied patients are shown in Table 1. Age, gender, BMI,
and lipid profiles were similar among groups. Prevalence
of clinical risk factors including diabetes, hypertension,
smoking, low HDL and CHD were also similar among the
3 groups. Plasma PLTP activity was significantly higher in
subjects with 'CC' polymorphism than that in subjects
with 'GG' and 'GC' polymorphisms (26.7 ± 12.8 pmol/
μL/hr vs. 23.7 ± 14.7/24.7 ± 14.0 pmol/μL/hr; p = 0.04).
Testing with an LSD test, subjects with 'CC' polymor-
phism had significantly higher PLTP activity as compared
to those with 'GG' one (P = 0.02). However, no statistical
significant difference of PLTP activity was found between
the 'CC' and 'GC' groups (P = 0.26). The similar result was
found between the 'GG' and 'GC' groups (P = 0.07).
As shown in Table 2, based on univariate analyses, plasma
PLTP activity was significantly associated with male gen-
der, presence of low HDL and with PLTP genotype. In
multivariable-adjusted analysis, the effect of gender was
attenuated though low HDL and PLTP genotype remained
independently associated with PLTP activity.
We next sought to evaluate PLTP activity and its relation
with plasma lipid levels. In univariate analysis, PLTP activ-
ity was significantly positively associated with plasma trig-
lyceride (TG), apolipoprotein (apo)B and apoE, while it
was negatively associated with plasma HDL and apoA-I.
The effect of plasma TG was attenuated on multivariable-
adjusted analysis (Table 3).
Discussion
The major finding of our study is that PLTP activity
inversely associated with plasma HDL-C levels. Impor-
tantly, the significant relation between PLTP activity and
HDL-C persisted even after adjustment for age, gender,
BMI and presence or absence of significant CHD.
Table 1: Patient Characteristics.
Characteristics† PLTP* genotype (N) p-value‡
gg (277) gc(276) cc(69)
Age (years) 61.3 ± 10.5 63.3 ± 9.9 63.0 ± 9.4 0.06
Gender
Men (%) 211(76.2) 222(80.4) 54(78.3) 0.64
Women (%) 65(23.5) 54(19.6) 15(21.7)
BMI§ (kg/m2) 24.7 ± 2.9 24.5 ± 2.9 24.5 ± 3.2 0.55
Diabetes (%) 56(20.21) 51(18.5) 11(15.9) 0.69
Hypertension (%) 171(61.7) 175(63.4) 23(33.3) 0.77
Smoking (%) 126(45.5) 133(48.2) 29(42.0) 0.61
CHD|| (%) 176(63.5) 189(68.4) 42(60.8) 0.33
PLTP activity (pmol/μl/h)n 23.7 ± 14.7 24.7 ± 14.0 26.7 ± 12.8 0.04
0.02†† (cc vs gg)
0.26 †† (cc vs gc)
0.07 †† (gg vs gc)
Total-C¶ (mmol/L) 4.71 ± 0.96 4.41 ± 1.03 4.40 ± 0.99 0.74
TG# (mmol/L) 1.74 ± 0.87 1.71 ± 1.08 1.8 ± 0.99 0.79
LDL-C (mmol/L) 2.65 ± 0.85 2.60 ± 0.88 2.55 ± 0.89 0.67
HDL-C (mmol/L) 1.03 ± 0.26 1.04 ± 0.29 1.01 ± 0.27 0.94
Low HDL-C (<0.8 mmol/L) (%) 81(29.2) 80(29.0) 21(30.4) 0.94
LDL-C/HDL-C 2.74 ± 1.28 2.63 ± 0.99 2.71 ± 1.24 0.50
ApoA-I** (g/L) 1.07 ± 0.19 1.06 ± 0.21 1.03 ± 0.21 0.18
apoB (g/L) 0.82 ± 0.42 0.82 ± 0.42 0.79 ± 0.26 0.87
apoE (mg/L) 47.99 ± 25.57 47.34 ± 18.39 45.17 ± 13.00 0.63
Lp(a)n (mg/L) 179.76 ± 157.41 202.89 ± 187.61 199.51 ± 227.73 0.30
* PLTP = Phospholipid transfer protein; † Means are presented ± standard deviation; ‡ p-values for differences in means were calculated using t test 
statistics, p-values for differences in proportions were calculated using Pearson's X2 test, †† p-values for differences using an LSD test for multiple 
comparisons; § BMI = body mass index; || CHD = Coronary Heart Disease with ≥50% coronary artery stenosis; n compared after log10 
transformation; ¶ Cholesterol; # Triglycerides; ** Apolipoprotein.Nutrition & Metabolism 2009, 6:49 http://www.nutritionandmetabolism.com/content/6/1/49
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There is growing evidence that the biological role(s) of
PLTP is related to HDL metabolism. Transgenic mice that
overexpressing human PLTP at high levels were previously
been generated. Compared with WT mice, these mice
show a 2.5-4.5-fold increase in PLTP activity in plasma
[15]. The overexpression of PLTP resulted in a significant
decrease of plasma levels of HDL-C[15], increase the for-
mation of preβ-HDL[15], increase catabolism
HDL[16,17], increased atherosclerosis[18], compared
with plasma from WT mice. We created PLTP gene knock-
out (KO) mice[19] which showed a marked decrease in
HDL-C, phospholipid, and apoA-I. Furthermore, the HDL
of the PLTP KO mice was enriched with protein and poor
in phosphatidylcholine, and turnover studies showed a 4-
fold increase in the catabolism of HDL protein and CE
compared with that of WT mice [20,21]. Interestingly,
both PLTP transgenic and KO mice showed the same phe-
notype, in terms of HDL levels. These studies could not
provide a prediction for the relationship between PLTP
activity and HDL levels in humans. Thus far the results
from human studies are controversial. Human plasma
PLTP activity and HDL levels have been shown to corre-
late either positively or negatively in different populations
[2,7-9]. In the present study, we chose a relatively large (n
= 622) and relatively uniform cohort and found that,
indeed, PLTP activity is inversely related with HDL levels.
Table 2: Univariate and multivariate estimates of PLTP activity levels.
Variable Unadjusted estimated PLTP† activity 
(Mean ± SE)




Male 21.20 ± 1.03 0.03 24.15 ± 1.06 0.52
Female 18.27 ± 1.06 23.01 ± 1.08
Diabetes
Present 22.66 ± 1.06 0.08 24.38 ± 1.07 0.35
Absent 20.05 ± 1.03 22.80 ± 1.05
Hypertension
Present 20.13 ± 1.04 0.36 22.86 ± 1.05 0.27
Absent 21.21 ± 1.05 24.38 ± 1.06
Smoking
Smoker 21.58 ± 1.04 0.09 24.04 ± 1.07 0.52
Nonsmoker 21.58 ± 1.04 23.12 ± 1.05
CHD‡
Present 20.70 ± 1.03 0.68 23.50 ± 1.05 0.93
Absent 20.21 ± 1.05 23.66 ± 1.07
Low HDL-C§
Present 27.20 ± 1.05 <0.01 28.18 ± 1.06 <0.01
Absent 18.46 ± 1.03 19.77 ± 1.05
PLTP Polymorphism Type
gg 19.41 ± 1.04 0.03 21.18 ± 1.05 0.03
cg 21.26 ± 1.04 23.50 ± 1.06
cc 23.59 ± 1.09 26.36 ± 1.09
* Covariates appearing in the multivariate model were evaluated at values of age = 62.43 years and BMI = 25.21 kg/m2; † PLTP= Phospholipid 
transfer protein; ‡ CHD = Coronary Heart Disease with ≥50% coronary artery stenosis; § Low HDL-C defined as HDL-cholesterol level <0.8 
mmol/L.
Table 3: Univariate and multivariate plasma lipid correlates of PLTP activity
Predictor variables Unadjusted expected change in PLTP 
activity (Units)
p-value Adjusted† expected change in PLTP† 
activity (Units)
p-value
Total-Cholesterol, per mmol/L -1.01 0.06 -1.01 0.05
Triglycerides, per mmol/L 1.03 0.01 -1.00 0.92
HDL-Cholesterol, per mmol/L -1.15 <0.01 1.27 <0.01
LDL-Cholesterol, per mmol/L -1.01 0.35 -1.01 0.18
apoA-I, per g/L -1.48 <0.01 -1.75 <0.01
apoB, per g/L 1.09 <0.01 1.10 <0.01
apoE, per mg/L 1.00 <0.01 1.00 <0.01
Lp(a), per mg/L 1.03 0.29 1.05 0.11
PLTP = Phospholipid transfer protein; † Adjusted for age, gender, BMI, PLTP Polymorphism, and presence or absence of significant CHD.Nutrition & Metabolism 2009, 6:49 http://www.nutritionandmetabolism.com/content/6/1/49
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Why low-HDL subjects with higher PLTP activity? It is
known that in addition to promoting transfer of phos-
pholipids from VLDL and chylomicron into HDL[19],
PLTP may contribute to the remodelling of HDL particles.
PLTP activity contributes to the generation of large HDL as
well as small HDL particles [22,23] and may promote
catabolism of these particles, thus decreasing HDL levels.
Besides PLTP, there is cholesteryl ester transfer protein
(CETP) in human plasma. It is well known that CETP
activity is inversely related with HDL[24]. Although PLTP
has no CE transfer activity, it can promote CETP activity
[25]. We also reported that PLTP KO/CETP transgenic
mice have significantly less CETP activity than that in
CETP transgenic mice[26]. High PLTP activity might pro-
mote CETP activity, thus decreasing HDL levels in human
plasma. It is known that PLTP function extends far beyond
phospholipid transfer and exchange among lipoproteins.
In mice, PLTP deficiency has been associated with a reduc-
tion in systemic inflammation [27,28]. Furthermore, in
mouse models, PLTP deficiency has been associated with
increased antioxidation potential[29], while the opposite
has been observed in PLTP overexpression [30]. In addi-
tion, PLTP is also involved in ABCA1-dependent choles-
terol efflux, a process which is critical for reverse
cholesterol transport [31,32]. Finally, PLTP activity is
closely related to obesity, diabetes mellitus, insulin resist-
ance [3-6], left ventricular systolic dysfunction [33], and
intima-media thickness[34]. Although the mechanism of
these associations remains poorly defined, it is likely
related to the putative role of PLTP in the development of
atherosclerosis, a common underlying factor in each of
these disease states.
In this study, we also found PLTP activity is positively
related to plasma apoB levels (Table 3). We and other
researchers have reported previously that PLTP deficiency
in mice results in markedly decreased in apoB-containing
lipoproteins in the circulation[35] and PLTP overexpres-
sion stimulation of VLDL secretion[36]. This effect may
well have an impact on atherogenesis.
In addition, we found a PLTP polymorphism (rs2294213)
has impact on PLTP activity. Plasma PLTP activity was
higher in subjects with 'CC' polymorphism than that in
subjects with 'GG' and 'GC' polymorphisms (26.7 ± 12.8
pmol/μL/hr vs. 23.7 ± 14.7/24.7 ± 14.0 pmol/μL/hr; p =
0.04). However, LSD test showed that except 'CC' vs 'GG'
groups, there was no statistical significant difference
between the 'CC' and 'GC' or 'GG' and 'GC' groups. Since
there were no statistically significant associations between
other polymorphisms and plasma PLTP activity [2,10],
the effect of rs2294213 polymorphism on PLTP activity
might be marginal.
Engler et al[12] reported that, in non-Hispanic white sam-
ple of subjects, allele frequency of rs2294213 accounted
for 2.2%, 4.3%, and 7.0% in hypoalphalipoproteinemia,
controls, and hyperalphalipoproteinemia groups, respec-
tively, and this polymorphism is responsible for the
increasing of HDL-C. However, the allele frequency in our
study (33%) is much higher than theirs [12] and we did
not observe the effect of this polymorphism on HDL-C
levels. The different study population might explain the
different allele frequency and different influences towards
lipid levels. The relative frequency of the CC polymor-
phism and its relation to HDL levels merits further study.
We have reported PLTP activity is an independent risk fac-
tor for CHD[1], but we do not find the association
between PLTP activity and CHD in this Chinese popula-
tion, which is inconsistent with our precious study in a
well-controlled and big size population [1]. This might be
related to the relatively small number of patients with
normal or non-obstructive CHD in our study population.
Conclusion
Human plasma PLTP activity was inversely associated
with HDL levels and positively related to plasma apoB lev-
els in this Chinese population. Although our findings
need to be confirmed in additional studies, they hold the
promise that PLTP might be therapeutic target for the
treatment of atherosclerosis.
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